Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

The FDA granted orphan designation to Sanofi US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Discover th ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Bernstein analyst Florent Cespedes maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €114.00. The ...

Sanofi Consumer Healthcare India Q4 Results 2025 on 21 Feb, 2025: Revenue decreased by 20.53% YoY & profit decreased by 34.66% YoY, profit at ₹44.3 crore and revenue at ₹170.7 crore.

Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.

The company announced its Q4 results after-market hours. Its shares ended 0.4% higher on Thursday at ₹4,759.35 on the BSE.